Securities code: 300534 securities abbreviation: Gansu Longshenrongfa Pharmaceutical Industry Co.Ltd(300534) Announcement No.: 2021-054
Gansu Longshenrongfa Pharmaceutical Industry Co.Ltd(300534)
Stock trading abnormal fluctuation and risk warning announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special risk tips:
1. According to the industry P / E ratio data of the CSRC published on the official website of China Securities Index Co., Ltd, The average p / E ratio of the company’s industry (C27 pharmaceutical manufacturing industry) in recent one month is 38.65. As of the closing on December 24, 2021, the latest rolling P / E ratio of the company is 557.03, which is much higher than the average level of Listed Companies in the same industry. Investors are specially reminded to pay attention to investment risks and do not blindly follow the trend.
2. After the company’s self-examination and verification with the controlling shareholder and actual controller, as of the disclosure date of this announcement, the company has no material information that should be disclosed but not disclosed.
3. From December 17, 2021 to December 24, 2021, the closing price of the company’s A-share stock increased by about 73.86%, and the gem composite index decreased by about 4.89% in the same period. The company’s stock fluctuated greatly relative to the gem composite index. In view of the large fluctuation of the company’s stock price in the short term, please pay full attention to the company’s risk tips, based on understanding the company’s business and products, pay attention to the transaction risk of the secondary market, make rational decisions and invest cautiously.
1、 Details of abnormal fluctuations in stock trading
Gansu Longshenrongfa Pharmaceutical Industry Co.Ltd(300534) (hereinafter referred to as ” Gansu Longshenrongfa Pharmaceutical Industry Co.Ltd(300534) ” or “the company”) has accumulated more than 30% deviation from the closing price increase for three consecutive trading days (December 22, 2021, December 23, 2021 and December 24, 2021). According to the relevant provisions of the special provisions on GEM stock trading of Shenzhen Stock Exchange, it is an abnormal fluctuation in stock trading.
2、 Description of the company’s concern and verification
In view of the abnormal fluctuation of the company’s stock trading, the board of directors of the company has re verified the controlling shareholders, actual controllers, directors, supervisors and senior managers of the company through telephone and on-site inquiry. The relevant information is described as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage;
2. The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently;
3. There has been no significant change in the company’s business situation and internal and external business environment recently;
4. Gansu Longshenrongfa Pharmaceutical Industry Co.Ltd(300534) due to planning to issue shares and pay cash to buy assets and raise supporting funds, upon application, On April 26, 2021, the company issued the suspension announcement on planning to issue shares, pay cash to purchase assets and raise supporting funds (Announcement No.: 2021-023). The trading of the company’s shares was suspended from the morning of April 26, 2021. During the suspension period, the company issued a suspension progress announcement every five trading days and issued it on May 6, 2021 Announcement on the progress of suspension of trading on planning to issue shares, pay cash to purchase assets and raise supporting funds (Announcement No.: 2021-026).
On May 11, 2021, the fourth meeting of the Fourth Board of directors of the company deliberated and adopted the
< Gansu Longshenrongfa Pharmaceutical Industry Co.Ltd(300534) 发行股份及支付现金购买资产并募集配套资金暨关联交易预案>
And its abstract. For details, see the relevant announcement disclosed by the company on cninfo.com on May 13, 2021. At the same time, the company disclosed the announcement on general risk tips on issuing shares, paying cash to purchase assets and raising supporting funds and resumption of trading of the company’s shares (Announcement No.: 2021-033). Upon application to Shenzhen Stock Exchange, the trading of the company’s shares resumed from the opening of the market on the morning of May 13, 2021.
On June 12, July 13, August 13, September 13, October 13, November 13, 2021 On December 13, the announcement on the progress after the disclosure of the plan for issuing shares and paying cash to purchase assets and raising supporting funds and related party transactions and the announcement on the progress of issuing shares and paying cash to purchase assets and raising supporting funds and related party transactions and the inability to issue the notice of convening the general meeting of shareholders within the specified time were issued on cninfo.com (Announcement No.: 2021-051), etc.
Since the first meeting of the board of directors and the disclosure of this transaction plan, the company and relevant parties have actively promoted all work of this transaction. As of the date of disclosure of this announcement, due to the failure to complete the audit and confirmation of the preliminary audit and evaluation results as planned, the validity period of the preliminary financial data and evaluation report of this transaction is about to expire. In order to ensure the orderly progress of the follow-up work, the company has negotiated with all parties to the transaction and agreed to redefine the base date of audit and evaluation and carry out a new phase of audit and evaluation, After the completion of relevant work, the board of directors will be reconvened to consider the issue of shares to purchase assets, and the company will perform relevant approval and information disclosure procedures in accordance with relevant laws and regulations.
With regard to this major asset restructuring, the company has fulfilled the obligation of information disclosure in strict accordance with the relevant provisions of the CSRC and Shenzhen Stock Exchange, and there is no situation that should be disclosed but not disclosed.
5. During the period of abnormal stock fluctuation, the controlling shareholder and actual controller of the company do not buy or sell the company’s shares.
3、 Description that there is no information that should be disclosed but not disclosed
The board of directors of the company confirms that, except for the aforesaid matters of planning to issue shares and pay cash to purchase assets and raise supporting funds, the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the GEM Listing Rules of Shenzhen stock exchange; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the GEM Listing Rules of Shenzhen Stock Exchange and has a great impact on the trading price of the company’s shares and their derivatives; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Relevant risk tips
1. Since December 17, 2021, Gansu Longshenrongfa Pharmaceutical Industry Co.Ltd(300534) stock price has been limited for three consecutive trading days. As of the date of disclosure of this announcement, there are four trading days. From December 17, 2021 to December 24, 2021, the closing price of the company’s shares increased by about 73.86%, and the gem composite index fell by about 4.89% in the same period. The company’s shares fluctuated greatly relative to the gem composite index. The stock price of the company has increased greatly in the short term. Please pay attention to the trading risk of the secondary market, make rational decisions and invest prudently.
2. Through self-examination, the company does not violate the fair disclosure of information. The company will continue to fulfill the obligation of information disclosure in strict accordance with the provisions and requirements of relevant laws and regulations, and do a good job of information disclosure in time.
3. The net profit of the company in the first three quarters of 2021 was -8.1868 million yuan, the net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses was -15.6122 million yuan, and the company suffered a loss in the first three quarters. Please pay attention to the announcement of the company and invest cautiously.
4. The above major asset restructuring plan needs to be reconsidered by the company’s board of directors, approved by Gansu SASAC and reviewed and approved by the company’s general meeting of shareholders, and can be formally implemented only after it is reviewed and approved by Shenzhen Stock Exchange and registered and approved by China Securities Regulatory Commission. There is uncertainty about whether the transaction can be approved by relevant departments and the time of final approval. The company solemnly reminds investors to make prudent decisions and pay attention to investment risks.
5. Securities times, Securities Daily, China Securities News, Shanghai Securities News and cninfo (www.cn. Info. Com.. CN) are the information disclosure media selected by the company. All information of the company shall be subject to the information published in the above designated media. Investors are invited to invest rationally and pay attention to risks.
It is hereby announced.
Gansu Longshenrongfa Pharmaceutical Industry Co.Ltd(300534) board of directors December 24, 2021
